Internal Medicine, Endocrinology, Diabetes, & Metabolism · Huntsville, AL
NPI
1467899120
Since 2013
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
401 Lowell Dr SE Ste 14
Huntsville, AL, 35801
Phone (256) 265-7660
Groups this clinician bills Medicare through
Medicare paid, 2024
$69K
1,230 services
Medicare patients, 2024
432
Average age 72
Drug cost, 2024
$1.9M
4,481 prescriptions
Company payments, 2025
$1,171
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joshua M Tate was code 99214 (office e&m - established), 491 times for 288 patients. In total Joshua M Tate billed 1,230 services in 12 codes, and Medicare paid $69K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-08-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 491 | 288 | $60.82 | $30K |
| 99232 Hospital E&M - Subsequent | Facility | 282 | 74 | $56.22 | $16K |
| 99204 Office E&M - New | Facility | 124 | 124 | $85.11 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 121 | 113 | $11.99 | $1,451 |
| 95251 Test - Miscellaneous | Facility | 117 | 73 | $22.61 | $2,645 |
| 99222 Hospital E&M - Initial | Facility | 62 | 60 | $86.30 | $5,351 |
| 99215 Office E&M - Established | Facility | 19 | 13 | $93.65 | $1,779 |
By year: 2022 $22K for 316 services; 2023 $63K for 925 services; 2024 $69K for 1,230 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joshua M Tate prescribed most often to Medicare patients was Glipizide Er (Glipizide), with 447 prescriptions and refills. In total Joshua M Tate wrote 4,481 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Glipizide Er Glipizide | 447 | 1,171 | 145 | $13K |
| Levothyroxine Sodium Generic | 444 | 1,160 | 134 | $6,248 |
| Mounjaro Tirzepatide | 343 | 378 | 55 | $379K |
| Liothyronine Sodium Generic | 318 | 790 | 98 | $14K |
| Jardiance Empagliflozin | 288 | 517 | 73 | $295K |
| Ozempic Semaglutide | 227 | 264 | 46 | $238K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 167 | 345 | 56 | $28K |
| Metformin Hcl Er Metformin Hcl | 157 | 414 | 61 | $2,011 |
| Rybelsus Semaglutide | 118 | 156 | 33 | $142K |
| Trulicity Dulaglutide | 106 | 129 | 17 | $122K |
| Humalog Kwikpen U-100 Insulin Lispro | 101 | 176 | 35 | $33K |
| Pioglitazone Hcl Generic | 97 | 179 | 19 | $1,053 |
| Farxiga Dapagliflozin Propanediol | 80 | 111 | 16 | $60K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 77 | 101 | 16 | $69K |
| Januvia Sitagliptin Phosphate | 75 | 125 | 20 | $67K |
Brand drugs: 2,356 claims; generic drugs: 1,854 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joshua M Tate $1,171 ($1,171 in general payments such as food, travel and fees) from 14 companies. The largest payer was Insulet Corporation with $246.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 18 | $246 |
| Novo Nordisk Inc NVO | 33 | $236 |
| Medtronic, Inc. MDT | 11 | $152 |
| Dexcom, Inc. DXCM | 9 | $137 |
| Abbott Laboratories ABT | 5 | $100 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $61.84 |
| Xeris Pharmaceuticals, Inc. | 3 | $59.42 |
| Amgen Inc. AMGN | 2 | $38.5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37.38 |
| Ascendis Pharma Endocrinology Inc ASND | 1 | $24.95 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.